ストックスクリーナーアプリを入手
34.21
1.55%
-0.54
アフターアワーズ：
34.21
前日終値:
$34.75
開ける：
$34.275
24時間の取引高:
6.28M
Relative Volume:
0.91
時価総額：
$24.71B
収益：
$8.26M
当期純損益:
$-397.91M
株価収益率:
-67.93
EPS:
-0.5036
ネットキャッシュフロー:
$-758.56M
1週間 パフォーマンス:
-3.63%
1か月 パフォーマンス:
-17.53%
6か月 パフォーマンス:
+21.44%
1年 パフォーマンス:
+113.41%
1日の値動き範囲:
$33.32
$34.56
1週間の範囲:
$33.32
$36.34
52週間の値動き範囲:
$15.90
$42.50
Roivant Sciences Ltd Stock (ROIV) Company Profile
Compare ROIV vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.21 | 25.86B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
503.25 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
197.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
739.57 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.63 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.12 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Bernstein | Outperform |
| 2025-09-02 | 開始されました | Citigroup | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-01-05 | 開始されました | Piper Sandler | Overweight |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-17 | 開始されました | Guggenheim | Buy |
| 2023-06-08 | 開始されました | BofA Securities | Neutral |
| 2022-10-27 | 開始されました | JP Morgan | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 開始されました | Goldman | Buy |
| 2021-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-28 | 開始されました | Citigroup | Buy |
| 2021-10-26 | 開始されました | Cowen | Outperform |
| 2021-10-26 | 開始されました | Jefferies | Buy |
| 2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo! Finance Canada
After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Roivant Sciences Ltd (ROIV) Stock Price Target & Forecast - TradingKey
Roivant Sciences gains as investors appear to keep rewarding recent clinical and regulatory momentum - Quiver Quantitative
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months - Yahoo Finance
Form 4 Roivant Sciences Ltd. For: 28 September By Investing.com - Investing.com Nigeria
Bernstein Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $41 - Moomoo
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance Singapore
Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging? - Yahoo Finance
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com Canada
ROIV Looks 361.0% Overvalued on GF Value™ - GuruFocus
Why Is Immunovant Stock Falling Wednesday?Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT) - Benzinga
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss - Yahoo Finance
Roivant slips on trial setback for Immunovant (ROIV:NASDAQ) - Seeking Alpha
A skin-lupus drug study missed its main goal. Its developer plans to stop testing it. - Stock Titan
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan
Form 4 Roivant Sciences Ltd. For: 22 September By Investing.com - Investing.com Australia
Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan
Why Roivant Sciences (ROIV) Is Back In The Spotlight - simplywall.st
Transcript : Roivant Sciences Ltd. Presents at Bank of America Global Healthcare Conference 2026, Sep-22-2026 12 - marketscreener.com
Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Analyzing a 20% Potential Upside Amid Biotech Innovation - DirectorsTalk Interviews
Did Positive PH ILD Trial Data Just Shift Roivant Stock Investment Narrative? - simplywall.st
Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan
Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan
New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan
Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan
Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan
Director at Roivant (ROIV) receives new stock awards - Stock Titan
What Is Roivant Sciences (ROIV) Signaling With Its Positive PH ILD Trial Data? - Yahoo Finance
Director Melissa Epperly Sells 4,938 Shares of Roivant Sciences Ltd (ROIV) - gurufocus.com
Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan
Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan
ROIV Initiates Coverage by Stifel -- Price Target Announced at $51 - GuruFocus
Roivant Sciences Price Target Announced at $51.00/Share by Stifel - Moomoo
Stifel Initiates Roivant Sciences(ROIV.US) With Buy Rating, Announces Target Price $51 - Moomoo
Stifel initiates Roivant Sciences stock with buy rating, $51 target By Investing.com - Investing.com South Africa
Stifel initiates Roivant Sciences stock with buy rating, $51 target - Investing.com
Roivant Sciences (ROIV) director lines up $930K stock sale - Stock Titan
Roivant Sciences (NASDAQ: ROIV) officer to sell 5,112 shares - Stock Titan
Why Roivant Sciences (ROIV) Stock Is Down Today - Quiver Quantitative
Roivant Sciences Director Melissa B. Epperly Forfeits 2,179 Shares at $40.94 Each (NASDAQ: ROIV) - Kalkine Media
Roivant Sciences (ROIV) director uses shares to cover tax bill - Stock Titan
Roivant Sciences (ROIV) director uses stock to cover tax bill - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Analysis: High Analyst Confidence with a 12.58% Upside Potential - DirectorsTalk Interviews
Roivant Sciences (ROIV) director uses shares to cover taxes - Stock Titan
ROIV gains commercial footing with LISRAYA appr... - Pluang
Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
Roivant Sciences Ltd (ROIV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Epperly Melissa B, | Director |
Oct 01 '26 |
Sale |
36.10 |
17,750 |
640,861 |
14,954 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Option Exercise |
3.85 |
200,000 |
770,000 |
1,799,154 |
| Venker Eric | President & Immunovant CEO |
Sep 30 '26 |
Sale |
36.62 |
200,000 |
7,324,000 |
1,599,154 |
0.97%
0.05%
大文字化:
|
ボリューム (24 時間):